Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Virtual Education

Virtual Education Program - COLT Meeting 2018 (Session 2)

 

Susan BranfordAgnes YONG w labcoat1  

 

                                        

 

Session 2: CML management, Practicalities
Chair: Prof. Tim Hughes

  • Molecular monitoring in CML
    (A/Prof Susan Branford)
  • Allograft - still a role in CML?
    (A/Prof Agnes Yong)

 

Virtual Education Program - COLT Meeting 2018 (Session 3)

 

Susan Branford

 

 David Ross David Yeung 3                  

  

Session 3: TFR in CML
Chair: Dr David Ross

  • Monitoring TFR - Challenges 
    (A/Prof Susan Branford)
  • TFR in CML - Clinical Trial Update
    (Dr David Ross)
  • Response definitions and endpoint determination 
    in CML clinical trials
    (Dr David Yeung)

 

Virtual Education Program - COLT Meeting 2018 (Session 4)

 

David Ross

 

 Devendra Hiwase Michael Osborn              

 

Session 4: CML Related Topics
Chair: A/Prof Agnes Yong

  • Management of Myelofibrosis
    (Dr David Ross)
  • MDS/MPN Overlap Syndrome
    (Dr Devendra Hiwase)
  • Pediatric CML
    (Dr Michael Osborn)

 

Virtual Education Program - COLT Meeting 2018 (Session 5)

 

Timothy Hughes                            

 

 Deborah White Agnes YONG w labcoat1              

 

Session 5: The CML frontier
Chair: Dr David Yeung

  • Making TFR Mainstream
    (Prof. Tim Hughes)
  • Prognostic biomarkers in CML
    (Prof. Deborah White)
  • The immunology of CML and immunomodulation
    (A/Prof Agnes Yong)

 

EHA 2018: Treatment options in resistant CML patients (Jane Apperley)

Presentations from the 23rd Congress of EHA 

We are pleased to make available a couple of presentations on various aspects of CML management that were first presented at the 23rd Congress of the European Hematology Association in Stockholm. Presentations include; treatment options in resistant CML patients, Does IFN-α improve outcome of CML in the TKI era? and TFR - a new goal for CP-CML patients?
 
EHA 2018 Apperley


Treatment options in resistant CML patients
Professor Jane Apperley, Imperial College London, UK 

  • Patient case history 2013 - 2017
  • ELN and NCCN definitions of response and failure
  • Outcome of 'real-life' 1st line imatinib by Sokol
  • Importance of ACA
  • ABL KD mutation sensitivity
  • CCyR rates for sequential use of NIL and DAS after IM failure
  • 3rd line therapy with Bosutinib
  • Relationship of line of therapy to efficacy for PON in 3rd-line vs. 4th line CML
  • SCT for CML: the EBMT score
We are very grateful for the support of Brandcast media to produce these webstreams.

EHA 2018: Does IFN-alpha improve outcome of CML in the TKI era? (Franck E. Nicolini)

Presentations from the 23rd Congress of EHA 

 
EHA 2018 Nicolini


Does IFN-α improve outcome of CML in the TKI era?
Dr Franck-Emmanuel Nicolini, Centre Hospitalier Universitaire de Lyon, France 

  • LSC persistence on TKI
  • IFN-α anti-tumorigenic activities
  • IFN-α alone and CML: last clinical data
  • What do we know nowadays about the combination of IFN-α and TKI?
  • IFN-α alone as maintenance therapy?
  • Conclusions
 We are very grateful for the support of Brandcast media to produce these webstreams.